



Halt or Delay Loss of Kidney Function In Patients with Diabetic Kidney Disease

**Lead clinical compound and 2 early-stage projects
Three different mode of actions**

Annual General Meeting

June 2022

SER150 Highlights


- ❖ SER150 has “Prove of Clinical Concept”, significantly decrease urinary protein in patients with Diabetic Kidney Disease
- ❖ SER150 CL-009 ongoing clinical study is recruiting patients in Australia and will add patients from New Zealand
- ❖ SER150 CL-009 will be handled by a new CRO with majority of activities based in Australia
- ❖ SER150 CL-009 will be a 6 months dosing study instead of a 3 months as previously described
- ❖ SER150 European Patent was published. PCT application was published
 - Claim: SER150 reduce renal inflammation
 - Priority date 2020

Diabetic Kidney Disease

The forgotten complication by most people

Diabetic Kidney Disease: No symptoms before 85-90% of kidney function is lost

Treatment:



SER150 inhibit directly and indirectly the low-grade inflammatory processes responsible for Diabetic Kidney Disease

SER150 significantly reduces protein in urine - Prove of Clinical Concept

Diabetic Kidney Disease

- Approximately 425 million patients have Diabetes World-Wide
- Still growing and expected growth of 25% the next 25 years
- Approximately 150 million patients have Diabetic Kidney Disease World-Wide

In the US:

- Approximately 100.000 new diabetic patients will annually enter chronic dialysis treatment or kidney transplantation

A Huge Market

SER150: Ongoing clinical study

SER150 CL-009 was approved by Australian ethical committees and relevant authorities just before introduction of the Covid19 pandemic

SER150 CL-009 has been seriously delayed due to Covid19 lock-down world-wide which has been the general situation for industries who were doing clinical studies

Serodus is changing CRO to an Australian CRO who has detailed knowledge about the Australian clinical managerial situation

SER150: Ongoing clinical study

Serodus and a Clinical Research Organization (CRO) will manage the clinical study in Australia and New Zealand.

Patients are suffering from Diabetic Kidney Disease and have

- reduced kidney function
- macroalbuminuria

Patients are dosed with

- SER150 for 6 month
- Anti-diabetics and anti-hypertensives

Serodus ASA, Financial Situation

The Company has cash to cover the majority of planned SER150 CL-009 activities, starting the year with € 4,3 M.

SER150 CL-009 study plan (2022-25) was approved under the Norwegian SkatteFUNN program, expected to support non-Australian cost for the company

Australian RDTI covering all SER150 CL-009 study cost in Australia will be applied for

Focus on Diabetic Nephropathy


Serodus was founded as a spin-off from Biomedicine Innovation (BMI) in Oslo, Norway

Pipeline:

Product	Discovery	Preclinical	Phase 1	Phase 2	Phase 3
SER150, T2D Nephropathy	[Progress bar spanning Discovery, Preclinical, Phase 1, and Phase 2]				
SER140, T2D Nephropathy	[Progress bar spanning Discovery and Preclinical]				
SER130, T2D Nephropathy	[Progress bar spanning Discovery and Preclinical]				

Management:

Dr. Eva Steiness – Chief Executive Officer & Chief Medical Officer



- MD, D.Sc., Professor, Clinical Pharmacology; 10 years in Internal Medicine, Dean Copenhagen University
- 30+ years' experience in the pharma & biotech industry
- Founded Zealand Pharma and was the CEO through 9 years
- Joined Serodus in 2011

Henrik Mordhorst – Chief Financial Officer



- M.Sc. Economics with 30+ years' experience in financial areas; investment banking (Merrill Lynch, Nomura, UBS), project financing and start-ups
- Previous position: CFO at Caladanian Group (UK)
- Joined Serodus in 2019

